

**ASX Announcement**9 November 2020

---

**Antisense Therapeutics to apply for dual listing on FSE (Frankfurt Stock Exchange)**

- **Supports strategy of broadening overseas investor base;**
- **Facilitates investment by institutional and retail investors across EU;**
- **Being established to increase corporate profile in Europe and trading liquidity**
- **Compatible with planned ATL1102 Phase IIb clinical trial of DMD in Europe**

Antisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY] is pleased to announce it has commenced proceedings to apply for the company to be dual listed on the Frankfurt Stock Exchange, the world's 10<sup>th</sup> largest Stock Exchange by market value.

Dual listing on the Frankfurt Stock Exchange supports the Company's strategy to broaden overseas investor base in line with the planned clinical development of ATL1102 in Europe and presents an opportunity for ANP to engage with biotech investors and facilitate investment from institutional and retail investors across the EU.

Antisense Therapeutics has appointed DGWA, the German Institute for Asset and Equity Allocation and Valuation (Deutsche Gesellschaft für Wertpapieranalyse GmbH) "DGWA" as its investor and corporate relations advisor in Europe.

DGWA, based in Frankfurt, the European financial heart, is the leading European investor relations and corporate advisory firm specialising in ASX listed companies dual-listed, or with operations, in Europe.

DGWA will focus on engaging retail, institutional and family office investors in the German speaking DACH region (Germany, Austria and Switzerland) with population of almost 100 million people as well as the rest of Europe.

DGWA will assist ANP to increase European investor awareness, develop European media awareness, organise virtual roadshows for investors and report on possible biotech collaborative opportunities within the euro-zone.

Mr. Stefan Müller, the CEO of DGWA, said "Introducing Antisense Therapeutics to Europe makes perfect sense. Many early stage biotech companies in Europe are owned privately or through venture capital. This increases the demand for quality, listed biotech companies. Also, German biotech investors are well acquainted with the possibilities and potential of antisense oligonucleotides.

Europe is home to several RNA therapy biotech companies, and investors understand the value creation from clinical trials success and milestones achieved by Antisense Therapeutics such as the recent receipt of both US FDA Rare Pediatric and Orphan drug Designations of ATL1102 for the treatment of Duchenne Muscular Dystrophy. We are confident the company will be well received by impact and biotech investors across Europe. The DACH region is noted for significant family office investment in biotech and, importantly, RNA-based technologies such as Antisense Therapeutics".

Mark Diamond, Chief Executive Officer of Antisense Therapeutics said: "We are delighted to be partnering with European investor relations and advisory firm DGWA with the mutual goal of expanding our global corporate and IR footprint and in turn our sophisticated biotech investor ownership. The move onto the Frankfurt exchange strongly aligns with our clinical development

plans for ATL1102 in Europe and the expectation of strong investor and corporate interest in our program.”

The Company will provide a further update when its application has been confirmed including timing for commencement of the listing.

*This announcement has been authorised for release by the Board.*

**For more information please contact:**

**Antisense Therapeutics**

Mark Diamond  
Managing Director  
+61 (0)3 9827 8999  
[www.antisense.com.au](http://www.antisense.com.au)

**Investment Enquiries**

Gennadi Koutchin  
XEC Partners  
[gkoutchin@xecpartners.com.au](mailto:gkoutchin@xecpartners.com.au)  
1300 932 037

**About Antisense Therapeutics Limited** (ASX:ANP | US OTC:ATHJY) is an Australian publicly listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne muscular dystrophy (DMD) patients and recently reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.

**About DGWA** Deutsche Gesellschaft für Wertpapieranalyse GmbH ("DGWA"), the German Institute for Asset and Equity Allocation and Valuation, is a boutique European investment and financial markets consulting firm based in Frankfurt and Berlin, Germany. The management team have a 25-year track record in trading, investing and analysing SME's around the world. DGWA has been involved in over 250 IPO's, financings, bond issues, dual listings, and corporate finance transactions as well as corresponding road shows and awareness campaigns.